As a dedicated oncologist specializing in non-small cell lung cancer (NSCLC), I have developed a particular expertise in the management of MET-driven disease, including patients harboring MET exon 14 (METex14) skipping mutations. With the emergence of MET-targeted therapies such as capmatinib and tepotinib, optimizing patient outcomes requires not only precision medicine but also a deep understanding of treatment-related toxicities and how to mitigate them effectively.
I had the privilege of chairing a group of consultants to develop a consensus on the expert management of toxicities from MET-targeted therapies, with a particular focus on drug-induced peripheral edema—a common yet often distressing side effect of these treatments. Through this initiative, we established practical strategies to optimize supportive care, enabling patients to remain on effective therapy while minimizing treatment-related morbidity.
Beyond toxicity management, I am actively involved in shaping contemporary treatment algorithms for MET-driven NSCLC, participating in key meetings and discussions that influence clinical practice. This includes evaluating the role of targeted therapy, immunotherapy, and combination strategies in different treatment settings.
In addition to my broader oncologic practice, I serve as co-chair of the The London Clinic Lung Cancer Multidisciplinary Team (MDT), where we develop individualized treatment plans tailored to the unique molecular and clinical profiles of each patient. Our MDT approach ensures that patients with MET-driven NSCLC receive the most evidence-based, personalized care, integrating the latest advancements in precision oncology.
Through clinical expertise, research collaborations, and leadership in multidisciplinary discussions, I remain committed to enhancing patient outcomes and advancing best practices in MET-driven NSCLC treatment.
Dr. Papadatos-Pastos at the 2025 British Thoracic Oncology Group (BTOG) Meeting in Belfast